Hispana. Acceso en línea al Patrimonio Cultural Digital Español

Está en:  › Dades de registre

A Descriptive Analysis of ATTR Amyloidosis in Spain from the Transthyretin Amyloidosis Outcomes Survey.

Identificadores del recurso

2193-8253

http://hdl.handle.net/10641/2742

10.1007/s40120-021-00267-y

Procedència

(Repositorio Institucional de la Universidad Francisco de Vitoria)

Fitxa

Títol:: A Descriptive Analysis of ATTR Amyloidosis in Spain from the Transthyretin Amyloidosis Outcomes Survey.
Descripció:: Introduction Transthyretin amyloidosis (ATTR amyloidosis) is a clinically heterogeneous disease caused by mutations in the transthyretin (TTR) gene or aggregation of wild-type transthyretin (ATTRwt). In Spain, there are two large endemic foci of ATTR amyloidosis caused by the Val30Met variant, with additional cases across the country; however, these data may be incomplete, as there is no centralized patient registry. The Transthyretin Amyloidosis Outcomes Survey (THAOS) is an ongoing, global, longitudinal, observational survey of patients with ATTR amyloidosis, including both inherited and wild-type disease, and asymptomatic patients with TTR mutations. This analysis aimed to gain a deeper understanding of the clinical profile of patients with ATTR amyloidosis in Spain. Methods This was a descriptive analysis of the demographic and clinical characteristics of symptomatic patients enrolled at six sites geographically dispersed throughout Spain (data cutoff: January 6, 2020). Patient data at enrollment, including genotype, demographics, and clinical presentation for symptomatic patients, were recorded. Patients were grouped by predominant phenotype based on clinical measures at enrollment: predominantly cardiac, predominantly neurologic, or mixed (cardiac and neurologic). Results There were 379 patients (58.0% male; 63.3% symptomatic) enrolled in the six THAOS sites in Spain. Predominant genotypes were the Val30Met mutation (69.1%) or ATTRwt (15.6%). Predominant phenotype distribution was neurologic (50.4%), mixed (35.8%), and cardiac (13.8%) for all symptomatic patients (n = 240); neurologic (67.8%), mixed (21.2%), and cardiac (11.0%) for symptomatic Val30Met (n = 146); and mixed (64.9%), cardiac (22.8%), and neurologic (12.3%) for symptomatic ATTRwt (n = 57). Symptomatic patients reported a range of ATTR amyloidosis signs and symptoms at enrollment, with autonomic neuropathy and sensory neuropathy common in all phenotypes. Conclusions These results from THAOS highlight the phenotypic heterogeneity associated with ATTR amyloidosis in Spain and the importance of comprehensive neurologic and cardiac evaluations in all patients with ATTR amyloidosis.; post-print; 392 KB
Idioma:: English
Relació:: https://link.springer.com/article/10.1007%2Fs40120-021-00267-y
Autor/Productor:: González Moreno, Juan; Losada López, Inés; Cisneros Barroso, Eugenia; García Pavía, Pablo; González Costello, José; Muñoz Beamud, Francisco; Campistol, Josep María; Fernández Torrón, Roberto; Chapman, Doug; Amass, Leslie
Editor:: Neurology and Therapy
Drets:: Atribución-NoComercial-SinDerivadas 3.0 España; http://creativecommons.org/licenses/by-nc-nd/3.0/es/; openAccess
Data:: 2022-01-27T13:13:46Z; 2021
Tipo de recurso:: article

oai_dc

Descarregar XML

<?xml version="1.0" encoding="UTF-8" ?>

<oai_dc:dc schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
1. <dc:title>A Descriptive Analysis of ATTR Amyloidosis in Spain from the Transthyretin Amyloidosis Outcomes Survey.</dc:title>
2. <dc:creator>González Moreno, Juan</dc:creator>
3. <dc:creator>Losada López, Inés</dc:creator>
4. <dc:creator>Cisneros Barroso, Eugenia</dc:creator>
5. <dc:creator>García Pavía, Pablo</dc:creator>
6. <dc:creator>González Costello, José</dc:creator>
7. <dc:creator>Muñoz Beamud, Francisco</dc:creator>
8. <dc:creator>Campistol, Josep María</dc:creator>
9. <dc:creator>Fernández Torrón, Roberto</dc:creator>
10. <dc:creator>Chapman, Doug</dc:creator>
11. <dc:creator>Amass, Leslie</dc:creator>
12. <dc:description>Introduction Transthyretin amyloidosis (ATTR amyloidosis) is a clinically heterogeneous disease caused by mutations in the transthyretin (TTR) gene or aggregation of wild-type transthyretin (ATTRwt). In Spain, there are two large endemic foci of ATTR amyloidosis caused by the Val30Met variant, with additional cases across the country; however, these data may be incomplete, as there is no centralized patient registry. The Transthyretin Amyloidosis Outcomes Survey (THAOS) is an ongoing, global, longitudinal, observational survey of patients with ATTR amyloidosis, including both inherited and wild-type disease, and asymptomatic patients with TTR mutations. This analysis aimed to gain a deeper understanding of the clinical profile of patients with ATTR amyloidosis in Spain. Methods This was a descriptive analysis of the demographic and clinical characteristics of symptomatic patients enrolled at six sites geographically dispersed throughout Spain (data cutoff: January 6, 2020). Patient data at enrollment, including genotype, demographics, and clinical presentation for symptomatic patients, were recorded. Patients were grouped by predominant phenotype based on clinical measures at enrollment: predominantly cardiac, predominantly neurologic, or mixed (cardiac and neurologic). Results There were 379 patients (58.0% male; 63.3% symptomatic) enrolled in the six THAOS sites in Spain. Predominant genotypes were the Val30Met mutation (69.1%) or ATTRwt (15.6%). Predominant phenotype distribution was neurologic (50.4%), mixed (35.8%), and cardiac (13.8%) for all symptomatic patients (n = 240); neurologic (67.8%), mixed (21.2%), and cardiac (11.0%) for symptomatic Val30Met (n = 146); and mixed (64.9%), cardiac (22.8%), and neurologic (12.3%) for symptomatic ATTRwt (n = 57). Symptomatic patients reported a range of ATTR amyloidosis signs and symptoms at enrollment, with autonomic neuropathy and sensory neuropathy common in all phenotypes. Conclusions These results from THAOS highlight the phenotypic heterogeneity associated with ATTR amyloidosis in Spain and the importance of comprehensive neurologic and cardiac evaluations in all patients with ATTR amyloidosis.</dc:description>
13. <dc:description>post-print</dc:description>
14. <dc:description>392 KB</dc:description>
15. <dc:date>2022-01-27T13:13:46Z</dc:date>
16. <dc:date>2022-01-27T13:13:46Z</dc:date>
17. <dc:date>2021</dc:date>
18. <dc:type>article</dc:type>
19. <dc:identifier>2193-8253</dc:identifier>
20. <dc:identifier>http://hdl.handle.net/10641/2742</dc:identifier>
21. <dc:identifier>10.1007/s40120-021-00267-y</dc:identifier>
22. <dc:language>eng</dc:language>
23. <dc:relation>https://link.springer.com/article/10.1007%2Fs40120-021-00267-y</dc:relation>
24. <dc:rights>Atribución-NoComercial-SinDerivadas 3.0 España</dc:rights>
25. <dc:rights>http://creativecommons.org/licenses/by-nc-nd/3.0/es/</dc:rights>
26. <dc:rights>openAccess</dc:rights>
27. <dc:publisher>Neurology and Therapy</dc:publisher>
</oai_dc:dc>

didl

Descarregar XML

<?xml version="1.0" encoding="UTF-8" ?>

<d:DIDL schemaLocation="urn:mpeg:mpeg21:2002:02-DIDL-NS http://standards.iso.org/ittf/PubliclyAvailableStandards/MPEG-21_schema_files/did/didl.xsd">
1. <d:DIDLInfo>
  1. <dcterms:created schemaLocation="http://purl.org/dc/terms/ http://dublincore.org/schemas/xmls/qdc/dcterms.xsd">2022-01-27T13:13:46Z</dcterms:created>
  </d:DIDLInfo>
2. <d:Item id="hdl_10641_2742">
  1. <d:Descriptor>
    1. <d:Statement mimeType="application/xml; charset=utf-8">
      1. <dii:Identifier schemaLocation="urn:mpeg:mpeg21:2002:01-DII-NS http://standards.iso.org/ittf/PubliclyAvailableStandards/MPEG-21_schema_files/dii/dii.xsd">urn:hdl:10641/2742</dii:Identifier>
      </d:Statement>
    </d:Descriptor>
  2. <d:Descriptor>
    1. <d:Statement mimeType="application/xml; charset=utf-8">
      1. <oai_dc:dc schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
        <dc:title>A Descriptive Analysis of ATTR Amyloidosis in Spain from the Transthyretin Amyloidosis Outcomes Survey.</dc:title>
        <dc:creator>González Moreno, Juan</dc:creator>
        <dc:creator>Losada López, Inés</dc:creator>
        <dc:creator>Cisneros Barroso, Eugenia</dc:creator>
        <dc:creator>García Pavía, Pablo</dc:creator>
        <dc:creator>González Costello, José</dc:creator>
        <dc:creator>Muñoz Beamud, Francisco</dc:creator>
        <dc:creator>Campistol, Josep María</dc:creator>
        <dc:creator>Fernández Torrón, Roberto</dc:creator>
        <dc:creator>Chapman, Doug</dc:creator>
        <dc:creator>Amass, Leslie</dc:creator>
        <dc:description>Introduction Transthyretin amyloidosis (ATTR amyloidosis) is a clinically heterogeneous disease caused by mutations in the transthyretin (TTR) gene or aggregation of wild-type transthyretin (ATTRwt). In Spain, there are two large endemic foci of ATTR amyloidosis caused by the Val30Met variant, with additional cases across the country; however, these data may be incomplete, as there is no centralized patient registry. The Transthyretin Amyloidosis Outcomes Survey (THAOS) is an ongoing, global, longitudinal, observational survey of patients with ATTR amyloidosis, including both inherited and wild-type disease, and asymptomatic patients with TTR mutations. This analysis aimed to gain a deeper understanding of the clinical profile of patients with ATTR amyloidosis in Spain. Methods This was a descriptive analysis of the demographic and clinical characteristics of symptomatic patients enrolled at six sites geographically dispersed throughout Spain (data cutoff: January 6, 2020). Patient data at enrollment, including genotype, demographics, and clinical presentation for symptomatic patients, were recorded. Patients were grouped by predominant phenotype based on clinical measures at enrollment: predominantly cardiac, predominantly neurologic, or mixed (cardiac and neurologic). Results There were 379 patients (58.0% male; 63.3% symptomatic) enrolled in the six THAOS sites in Spain. Predominant genotypes were the Val30Met mutation (69.1%) or ATTRwt (15.6%). Predominant phenotype distribution was neurologic (50.4%), mixed (35.8%), and cardiac (13.8%) for all symptomatic patients (n = 240); neurologic (67.8%), mixed (21.2%), and cardiac (11.0%) for symptomatic Val30Met (n = 146); and mixed (64.9%), cardiac (22.8%), and neurologic (12.3%) for symptomatic ATTRwt (n = 57). Symptomatic patients reported a range of ATTR amyloidosis signs and symptoms at enrollment, with autonomic neuropathy and sensory neuropathy common in all phenotypes. Conclusions These results from THAOS highlight the phenotypic heterogeneity associated with ATTR amyloidosis in Spain and the importance of comprehensive neurologic and cardiac evaluations in all patients with ATTR amyloidosis.</dc:description>
        <dc:date>2022-01-27T13:13:46Z</dc:date>
        <dc:date>2022-01-27T13:13:46Z</dc:date>
        <dc:date>2021</dc:date>
        <dc:type>article</dc:type>
        <dc:identifier>2193-8253</dc:identifier>
        <dc:identifier>http://hdl.handle.net/10641/2742</dc:identifier>
        <dc:identifier>10.1007/s40120-021-00267-y</dc:identifier>
        <dc:language>eng</dc:language>
        <dc:relation>https://link.springer.com/article/10.1007%2Fs40120-021-00267-y</dc:relation>
        <dc:rights>http://creativecommons.org/licenses/by-nc-nd/3.0/es/</dc:rights>
        <dc:rights>openAccess</dc:rights>
        <dc:rights>Atribución-NoComercial-SinDerivadas 3.0 España</dc:rights>
        <dc:publisher>Neurology and Therapy</dc:publisher>
        </oai_dc:dc>
      </d:Statement>
    </d:Descriptor>
  3. <d:Component id="10641_2742_1">
    1. <d:Resource mimeType="application/pdf" ref="http://ddfv.ufv.es/bitstream/10641/2742/1/Gonz%c3%a1lez-Moreno2021_Article_ADescriptiveAnalysisOfATTRAmyl.pdf" />
    </d:Component>
  </d:Item>
</d:DIDL>

dim

Descarregar XML

<?xml version="1.0" encoding="UTF-8" ?>

<dim:dim schemaLocation="http://www.dspace.org/xmlns/dspace/dim http://www.dspace.org/schema/dim.xsd">
1. <dim:field authority="fa7ef5b5-3e36-429f-b476-295de5cbf021" confidence="600" element="contributor" mdschema="dc" qualifier="author">González Moreno, Juan</dim:field>
2. <dim:field authority="634f961b-0bc7-44e1-8b68-f15d47087519" confidence="600" element="contributor" mdschema="dc" qualifier="author">Losada López, Inés</dim:field>
3. <dim:field authority="075e99bc-12eb-4054-a79b-da8365f9f32a" confidence="600" element="contributor" mdschema="dc" qualifier="author">Cisneros Barroso, Eugenia</dim:field>
4. <dim:field authority="73" confidence="600" element="contributor" mdschema="dc" qualifier="author">García Pavía, Pablo</dim:field>
5. <dim:field authority="2cf97701-b4f0-4377-bcd9-34bbb813ca00" confidence="600" element="contributor" mdschema="dc" qualifier="author">González Costello, José</dim:field>
6. <dim:field authority="d646ea11-0365-4d1b-b9c7-d6ec08b589a9" confidence="600" element="contributor" mdschema="dc" qualifier="author">Muñoz Beamud, Francisco</dim:field>
7. <dim:field authority="22cc147f-504c-4742-9e64-79bb03c00bee" confidence="600" element="contributor" mdschema="dc" qualifier="author">Campistol, Josep María</dim:field>
8. <dim:field authority="f56e70e6-2e95-4938-b391-089841395662" confidence="600" element="contributor" mdschema="dc" qualifier="author">Fernández Torrón, Roberto</dim:field>
9. <dim:field authority="aa892c9c-da39-4329-a4ec-a3cc155fc12d" confidence="600" element="contributor" mdschema="dc" qualifier="author">Chapman, Doug</dim:field>
10. <dim:field authority="327494ff-81c0-43fe-92a5-c91629a8ac29" confidence="600" element="contributor" mdschema="dc" qualifier="author">Amass, Leslie</dim:field>
11. <dim:field element="date" mdschema="dc" qualifier="accessioned">2022-01-27T13:13:46Z</dim:field>
12. <dim:field element="date" mdschema="dc" qualifier="available">2022-01-27T13:13:46Z</dim:field>
13. <dim:field element="date" mdschema="dc" qualifier="issued">2021</dim:field>
14. <dim:field element="identifier" lang="spa" mdschema="dc" qualifier="issn">2193-8253</dim:field>
15. <dim:field element="identifier" mdschema="dc" qualifier="uri">http://hdl.handle.net/10641/2742</dim:field>
16. <dim:field element="identifier" lang="spa" mdschema="dc" qualifier="doi">10.1007/s40120-021-00267-y</dim:field>
17. <dim:field element="description" lang="spa" mdschema="dc" qualifier="abstract">Introduction Transthyretin amyloidosis (ATTR amyloidosis) is a clinically heterogeneous disease caused by mutations in the transthyretin (TTR) gene or aggregation of wild-type transthyretin (ATTRwt). In Spain, there are two large endemic foci of ATTR amyloidosis caused by the Val30Met variant, with additional cases across the country; however, these data may be incomplete, as there is no centralized patient registry. The Transthyretin Amyloidosis Outcomes Survey (THAOS) is an ongoing, global, longitudinal, observational survey of patients with ATTR amyloidosis, including both inherited and wild-type disease, and asymptomatic patients with TTR mutations. This analysis aimed to gain a deeper understanding of the clinical profile of patients with ATTR amyloidosis in Spain. Methods This was a descriptive analysis of the demographic and clinical characteristics of symptomatic patients enrolled at six sites geographically dispersed throughout Spain (data cutoff: January 6, 2020). Patient data at enrollment, including genotype, demographics, and clinical presentation for symptomatic patients, were recorded. Patients were grouped by predominant phenotype based on clinical measures at enrollment: predominantly cardiac, predominantly neurologic, or mixed (cardiac and neurologic). Results There were 379 patients (58.0% male; 63.3% symptomatic) enrolled in the six THAOS sites in Spain. Predominant genotypes were the Val30Met mutation (69.1%) or ATTRwt (15.6%). Predominant phenotype distribution was neurologic (50.4%), mixed (35.8%), and cardiac (13.8%) for all symptomatic patients (n = 240); neurologic (67.8%), mixed (21.2%), and cardiac (11.0%) for symptomatic Val30Met (n = 146); and mixed (64.9%), cardiac (22.8%), and neurologic (12.3%) for symptomatic ATTRwt (n = 57). Symptomatic patients reported a range of ATTR amyloidosis signs and symptoms at enrollment, with autonomic neuropathy and sensory neuropathy common in all phenotypes. Conclusions These results from THAOS highlight the phenotypic heterogeneity associated with ATTR amyloidosis in Spain and the importance of comprehensive neurologic and cardiac evaluations in all patients with ATTR amyloidosis.</dim:field>
18. <dim:field element="description" lang="spa" mdschema="dc" qualifier="version">post-print</dim:field>
19. <dim:field element="description" lang="spa" mdschema="dc" qualifier="extent">392 KB</dim:field>
20. <dim:field element="language" lang="spa" mdschema="dc" qualifier="iso">eng</dim:field>
21. <dim:field element="publisher" lang="spa" mdschema="dc">Neurology and Therapy</dim:field>
22. <dim:field element="rights" lang="*" mdschema="dc">Atribución-NoComercial-SinDerivadas 3.0 España</dim:field>
23. <dim:field element="rights" lang="*" mdschema="dc" qualifier="uri">http://creativecommons.org/licenses/by-nc-nd/3.0/es/</dim:field>
24. <dim:field element="rights" lang="spa" mdschema="dc" qualifier="accessRights">openAccess</dim:field>
25. <dim:field element="title" lang="spa" mdschema="dc">A Descriptive Analysis of ATTR Amyloidosis in Spain from the Transthyretin Amyloidosis Outcomes Survey.</dim:field>
26. <dim:field element="type" lang="spa" mdschema="dc">article</dim:field>
27. <dim:field element="relation" lang="spa" mdschema="dc" qualifier="publisherversion">https://link.springer.com/article/10.1007%2Fs40120-021-00267-y</dim:field>
</dim:dim>

etdms

Descarregar XML

<?xml version="1.0" encoding="UTF-8" ?>

<thesis schemaLocation="http://www.ndltd.org/standards/metadata/etdms/1.0/ http://www.ndltd.org/standards/metadata/etdms/1.0/etdms.xsd">
1. <title>A Descriptive Analysis of ATTR Amyloidosis in Spain from the Transthyretin Amyloidosis Outcomes Survey.</title>
2. <creator>González Moreno, Juan</creator>
3. <creator>Losada López, Inés</creator>
4. <creator>Cisneros Barroso, Eugenia</creator>
5. <creator>García Pavía, Pablo</creator>
6. <creator>González Costello, José</creator>
7. <creator>Muñoz Beamud, Francisco</creator>
8. <creator>Campistol, Josep María</creator>
9. <creator>Fernández Torrón, Roberto</creator>
10. <creator>Chapman, Doug</creator>
11. <creator>Amass, Leslie</creator>
12. <description>Introduction Transthyretin amyloidosis (ATTR amyloidosis) is a clinically heterogeneous disease caused by mutations in the transthyretin (TTR) gene or aggregation of wild-type transthyretin (ATTRwt). In Spain, there are two large endemic foci of ATTR amyloidosis caused by the Val30Met variant, with additional cases across the country; however, these data may be incomplete, as there is no centralized patient registry. The Transthyretin Amyloidosis Outcomes Survey (THAOS) is an ongoing, global, longitudinal, observational survey of patients with ATTR amyloidosis, including both inherited and wild-type disease, and asymptomatic patients with TTR mutations. This analysis aimed to gain a deeper understanding of the clinical profile of patients with ATTR amyloidosis in Spain. Methods This was a descriptive analysis of the demographic and clinical characteristics of symptomatic patients enrolled at six sites geographically dispersed throughout Spain (data cutoff: January 6, 2020). Patient data at enrollment, including genotype, demographics, and clinical presentation for symptomatic patients, were recorded. Patients were grouped by predominant phenotype based on clinical measures at enrollment: predominantly cardiac, predominantly neurologic, or mixed (cardiac and neurologic). Results There were 379 patients (58.0% male; 63.3% symptomatic) enrolled in the six THAOS sites in Spain. Predominant genotypes were the Val30Met mutation (69.1%) or ATTRwt (15.6%). Predominant phenotype distribution was neurologic (50.4%), mixed (35.8%), and cardiac (13.8%) for all symptomatic patients (n = 240); neurologic (67.8%), mixed (21.2%), and cardiac (11.0%) for symptomatic Val30Met (n = 146); and mixed (64.9%), cardiac (22.8%), and neurologic (12.3%) for symptomatic ATTRwt (n = 57). Symptomatic patients reported a range of ATTR amyloidosis signs and symptoms at enrollment, with autonomic neuropathy and sensory neuropathy common in all phenotypes. Conclusions These results from THAOS highlight the phenotypic heterogeneity associated with ATTR amyloidosis in Spain and the importance of comprehensive neurologic and cardiac evaluations in all patients with ATTR amyloidosis.</description>
13. <date>2022-01-27</date>
14. <date>2022-01-27</date>
15. <date>2021</date>
16. <type>article</type>
17. <identifier>2193-8253</identifier>
18. <identifier>http://hdl.handle.net/10641/2742</identifier>
19. <identifier>10.1007/s40120-021-00267-y</identifier>
20. <language>eng</language>
21. <relation>https://link.springer.com/article/10.1007%2Fs40120-021-00267-y</relation>
22. <rights>http://creativecommons.org/licenses/by-nc-nd/3.0/es/</rights>
23. <rights>openAccess</rights>
24. <rights>Atribución-NoComercial-SinDerivadas 3.0 España</rights>
25. <publisher>Neurology and Therapy</publisher>
</thesis>

marc

Descarregar XML

<?xml version="1.0" encoding="UTF-8" ?>

<record schemaLocation="http://www.loc.gov/MARC21/slim http://www.loc.gov/standards/marcxml/schema/MARC21slim.xsd">
1. <leader>00925njm 22002777a 4500</leader>
2. <datafield ind1=" " ind2=" " tag="042">
  1. <subfield code="a">dc</subfield>
  </datafield>
3. <datafield ind1=" " ind2=" " tag="720">
  1. <subfield code="a">González Moreno, Juan</subfield>
  2. <subfield code="e">author</subfield>
  </datafield>
4. <datafield ind1=" " ind2=" " tag="720">
  1. <subfield code="a">Losada López, Inés</subfield>
  2. <subfield code="e">author</subfield>
  </datafield>
5. <datafield ind1=" " ind2=" " tag="720">
  1. <subfield code="a">Cisneros Barroso, Eugenia</subfield>
  2. <subfield code="e">author</subfield>
  </datafield>
6. <datafield ind1=" " ind2=" " tag="720">
  1. <subfield code="a">García Pavía, Pablo</subfield>
  2. <subfield code="e">author</subfield>
  </datafield>
7. <datafield ind1=" " ind2=" " tag="720">
  1. <subfield code="a">González Costello, José</subfield>
  2. <subfield code="e">author</subfield>
  </datafield>
8. <datafield ind1=" " ind2=" " tag="720">
  1. <subfield code="a">Muñoz Beamud, Francisco</subfield>
  2. <subfield code="e">author</subfield>
  </datafield>
9. <datafield ind1=" " ind2=" " tag="720">
  1. <subfield code="a">Campistol, Josep María</subfield>
  2. <subfield code="e">author</subfield>
  </datafield>
10. <datafield ind1=" " ind2=" " tag="720">
  1. <subfield code="a">Fernández Torrón, Roberto</subfield>
  2. <subfield code="e">author</subfield>
  </datafield>
11. <datafield ind1=" " ind2=" " tag="720">
  1. <subfield code="a">Chapman, Doug</subfield>
  2. <subfield code="e">author</subfield>
  </datafield>
12. <datafield ind1=" " ind2=" " tag="720">
  1. <subfield code="a">Amass, Leslie</subfield>
  2. <subfield code="e">author</subfield>
  </datafield>
13. <datafield ind1=" " ind2=" " tag="260">
  1. <subfield code="c">2021</subfield>
  </datafield>
14. <datafield ind1=" " ind2=" " tag="520">
  1. <subfield code="a">Introduction Transthyretin amyloidosis (ATTR amyloidosis) is a clinically heterogeneous disease caused by mutations in the transthyretin (TTR) gene or aggregation of wild-type transthyretin (ATTRwt). In Spain, there are two large endemic foci of ATTR amyloidosis caused by the Val30Met variant, with additional cases across the country; however, these data may be incomplete, as there is no centralized patient registry. The Transthyretin Amyloidosis Outcomes Survey (THAOS) is an ongoing, global, longitudinal, observational survey of patients with ATTR amyloidosis, including both inherited and wild-type disease, and asymptomatic patients with TTR mutations. This analysis aimed to gain a deeper understanding of the clinical profile of patients with ATTR amyloidosis in Spain. Methods This was a descriptive analysis of the demographic and clinical characteristics of symptomatic patients enrolled at six sites geographically dispersed throughout Spain (data cutoff: January 6, 2020). Patient data at enrollment, including genotype, demographics, and clinical presentation for symptomatic patients, were recorded. Patients were grouped by predominant phenotype based on clinical measures at enrollment: predominantly cardiac, predominantly neurologic, or mixed (cardiac and neurologic). Results There were 379 patients (58.0% male; 63.3% symptomatic) enrolled in the six THAOS sites in Spain. Predominant genotypes were the Val30Met mutation (69.1%) or ATTRwt (15.6%). Predominant phenotype distribution was neurologic (50.4%), mixed (35.8%), and cardiac (13.8%) for all symptomatic patients (n = 240); neurologic (67.8%), mixed (21.2%), and cardiac (11.0%) for symptomatic Val30Met (n = 146); and mixed (64.9%), cardiac (22.8%), and neurologic (12.3%) for symptomatic ATTRwt (n = 57). Symptomatic patients reported a range of ATTR amyloidosis signs and symptoms at enrollment, with autonomic neuropathy and sensory neuropathy common in all phenotypes. Conclusions These results from THAOS highlight the phenotypic heterogeneity associated with ATTR amyloidosis in Spain and the importance of comprehensive neurologic and cardiac evaluations in all patients with ATTR amyloidosis.</subfield>
  </datafield>
15. <datafield ind1="8" ind2=" " tag="024">
  1. <subfield code="a">2193-8253</subfield>
  </datafield>
16. <datafield ind1="8" ind2=" " tag="024">
  1. <subfield code="a">http://hdl.handle.net/10641/2742</subfield>
  </datafield>
17. <datafield ind1="8" ind2=" " tag="024">
  1. <subfield code="a">10.1007/s40120-021-00267-y</subfield>
  </datafield>
18. <datafield ind1="0" ind2="0" tag="245">
  1. <subfield code="a">A Descriptive Analysis of ATTR Amyloidosis in Spain from the Transthyretin Amyloidosis Outcomes Survey.</subfield>
  </datafield>
</record>

mets

Descarregar XML

<?xml version="1.0" encoding="UTF-8" ?>

<mets ID=" DSpace_ITEM_10641-2742" OBJID=" hdl:10641/2742" PROFILE="DSpace METS SIP Profile 1.0" TYPE="DSpace ITEM" schemaLocation="http://www.loc.gov/METS/ http://www.loc.gov/standards/mets/mets.xsd">
1. <metsHdr CREATEDATE="2022-09-20T09:20:10Z">
  1. <agent ROLE="CUSTODIAN" TYPE="ORGANIZATION">
    1. <name>DDFV</name>
    </agent>
  </metsHdr>
2. <dmdSec ID="DMD_10641_2742">
  1. <mdWrap MDTYPE="MODS">
    1. <xmlData schemaLocation="http://www.loc.gov/mods/v3 http://www.loc.gov/standards/mods/v3/mods-3-1.xsd">
      1. <mods:mods schemaLocation="http://www.loc.gov/mods/v3 http://www.loc.gov/standards/mods/v3/mods-3-1.xsd">
        <mods:name>
        <mods:role>
        <mods:roleTerm type="text">author</mods:roleTerm>
        </mods:role>
        <mods:namePart>González Moreno, Juan</mods:namePart>
        </mods:name>
        <mods:name>
        <mods:role>
        <mods:roleTerm type="text">author</mods:roleTerm>
        </mods:role>
        <mods:namePart>Losada López, Inés</mods:namePart>
        </mods:name>
        <mods:name>
        <mods:role>
        <mods:roleTerm type="text">author</mods:roleTerm>
        </mods:role>
        <mods:namePart>Cisneros Barroso, Eugenia</mods:namePart>
        </mods:name>
        <mods:name>
        <mods:role>
        <mods:roleTerm type="text">author</mods:roleTerm>
        </mods:role>
        <mods:namePart>García Pavía, Pablo</mods:namePart>
        </mods:name>
        <mods:name>
        <mods:role>
        <mods:roleTerm type="text">author</mods:roleTerm>
        </mods:role>
        <mods:namePart>González Costello, José</mods:namePart>
        </mods:name>
        <mods:name>
        <mods:role>
        <mods:roleTerm type="text">author</mods:roleTerm>
        </mods:role>
        <mods:namePart>Muñoz Beamud, Francisco</mods:namePart>
        </mods:name>
        <mods:name>
        <mods:role>
        <mods:roleTerm type="text">author</mods:roleTerm>
        </mods:role>
        <mods:namePart>Campistol, Josep María</mods:namePart>
        </mods:name>
        <mods:name>
        <mods:role>
        <mods:roleTerm type="text">author</mods:roleTerm>
        </mods:role>
        <mods:namePart>Fernández Torrón, Roberto</mods:namePart>
        </mods:name>
        <mods:name>
        <mods:role>
        <mods:roleTerm type="text">author</mods:roleTerm>
        </mods:role>
        <mods:namePart>Chapman, Doug</mods:namePart>
        </mods:name>
        <mods:name>
        <mods:role>
        <mods:roleTerm type="text">author</mods:roleTerm>
        </mods:role>
        <mods:namePart>Amass, Leslie</mods:namePart>
        </mods:name>
        <mods:extension>
        <mods:dateAccessioned encoding="iso8601">2022-01-27T13:13:46Z</mods:dateAccessioned>
        </mods:extension>
        <mods:extension>
        <mods:dateAvailable encoding="iso8601">2022-01-27T13:13:46Z</mods:dateAvailable>
        </mods:extension>
        <mods:originInfo>
        <mods:dateIssued encoding="iso8601">2021</mods:dateIssued>
        </mods:originInfo>
        <mods:identifier type="issn">2193-8253</mods:identifier>
        <mods:identifier type="uri">http://hdl.handle.net/10641/2742</mods:identifier>
        <mods:identifier type="doi">10.1007/s40120-021-00267-y</mods:identifier>
        <mods:abstract>Introduction Transthyretin amyloidosis (ATTR amyloidosis) is a clinically heterogeneous disease caused by mutations in the transthyretin (TTR) gene or aggregation of wild-type transthyretin (ATTRwt). In Spain, there are two large endemic foci of ATTR amyloidosis caused by the Val30Met variant, with additional cases across the country; however, these data may be incomplete, as there is no centralized patient registry. The Transthyretin Amyloidosis Outcomes Survey (THAOS) is an ongoing, global, longitudinal, observational survey of patients with ATTR amyloidosis, including both inherited and wild-type disease, and asymptomatic patients with TTR mutations. This analysis aimed to gain a deeper understanding of the clinical profile of patients with ATTR amyloidosis in Spain. Methods This was a descriptive analysis of the demographic and clinical characteristics of symptomatic patients enrolled at six sites geographically dispersed throughout Spain (data cutoff: January 6, 2020). Patient data at enrollment, including genotype, demographics, and clinical presentation for symptomatic patients, were recorded. Patients were grouped by predominant phenotype based on clinical measures at enrollment: predominantly cardiac, predominantly neurologic, or mixed (cardiac and neurologic). Results There were 379 patients (58.0% male; 63.3% symptomatic) enrolled in the six THAOS sites in Spain. Predominant genotypes were the Val30Met mutation (69.1%) or ATTRwt (15.6%). Predominant phenotype distribution was neurologic (50.4%), mixed (35.8%), and cardiac (13.8%) for all symptomatic patients (n = 240); neurologic (67.8%), mixed (21.2%), and cardiac (11.0%) for symptomatic Val30Met (n = 146); and mixed (64.9%), cardiac (22.8%), and neurologic (12.3%) for symptomatic ATTRwt (n = 57). Symptomatic patients reported a range of ATTR amyloidosis signs and symptoms at enrollment, with autonomic neuropathy and sensory neuropathy common in all phenotypes. Conclusions These results from THAOS highlight the phenotypic heterogeneity associated with ATTR amyloidosis in Spain and the importance of comprehensive neurologic and cardiac evaluations in all patients with ATTR amyloidosis.</mods:abstract>
        <mods:language>
        <mods:languageTerm authority="rfc3066">eng</mods:languageTerm>
        </mods:language>
        <mods:accessCondition type="useAndReproduction">Atribución-NoComercial-SinDerivadas 3.0 España</mods:accessCondition>
        <mods:titleInfo>
        <mods:title>A Descriptive Analysis of ATTR Amyloidosis in Spain from the Transthyretin Amyloidosis Outcomes Survey.</mods:title>
        </mods:titleInfo>
        <mods:genre>article</mods:genre>
        </mods:mods>
      </xmlData>
    </mdWrap>
  </dmdSec>
3. <amdSec ID="TMD_10641_2742">
  1. <rightsMD ID="RIG_10641_2742">
    1. <mdWrap MDTYPE="OTHER" MIMETYPE="text/plain" OTHERMDTYPE="DSpaceDepositLicense">
      1. <binData>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</binData>
      </mdWrap>
    </rightsMD>
  </amdSec>
4. <amdSec ID="FO_10641_2742_1">
  1. <techMD ID="TECH_O_10641_2742_1">
    1. <mdWrap MDTYPE="PREMIS">
      1. <xmlData schemaLocation="http://www.loc.gov/standards/premis http://www.loc.gov/standards/premis/PREMIS-v1-0.xsd">
        <premis:premis>
        <premis:object>
        <premis:objectIdentifier>
        <premis:objectIdentifierType>URL</premis:objectIdentifierType>
        <premis:objectIdentifierValue>http://ddfv.ufv.es/bitstream/10641/2742/1/Gonz%c3%a1lez-Moreno2021_Article_ADescriptiveAnalysisOfATTRAmyl.pdf</premis:objectIdentifierValue>
        </premis:objectIdentifier>
        <premis:objectCategory>File</premis:objectCategory>
        <premis:objectCharacteristics>
        <premis:fixity>
        <premis:messageDigestAlgorithm>MD5</premis:messageDigestAlgorithm>
        <premis:messageDigest>2dc05551fa3590638abb39e6d2ca1c1a</premis:messageDigest>
        </premis:fixity>
        <premis:size>400929</premis:size>
        <premis:format>
        <premis:formatDesignation>
        <premis:formatName>application/pdf</premis:formatName>
        </premis:formatDesignation>
        </premis:format>
        </premis:objectCharacteristics>
        <premis:originalName>González-Moreno2021_Article_ADescriptiveAnalysisOfATTRAmyl.pdf</premis:originalName>
        </premis:object>
        </premis:premis>
        </xmlData>
      </mdWrap>
    </techMD>
  </amdSec>
5. <amdSec ID="FT_10641_2742_4">
  1. <techMD ID="TECH_T_10641_2742_4">
    1. <mdWrap MDTYPE="PREMIS">
      1. <xmlData schemaLocation="http://www.loc.gov/standards/premis http://www.loc.gov/standards/premis/PREMIS-v1-0.xsd">
        <premis:premis>
        <premis:object>
        <premis:objectIdentifier>
        <premis:objectIdentifierType>URL</premis:objectIdentifierType>
        <premis:objectIdentifierValue>http://ddfv.ufv.es/bitstream/10641/2742/4/Gonz%c3%a1lez-Moreno2021_Article_ADescriptiveAnalysisOfATTRAmyl.pdf.txt</premis:objectIdentifierValue>
        </premis:objectIdentifier>
        <premis:objectCategory>File</premis:objectCategory>
        <premis:objectCharacteristics>
        <premis:fixity>
        <premis:messageDigestAlgorithm>MD5</premis:messageDigestAlgorithm>
        <premis:messageDigest>ff7568ade64998e584171ed6a158391b</premis:messageDigest>
        </premis:fixity>
        <premis:size>41276</premis:size>
        <premis:format>
        <premis:formatDesignation>
        <premis:formatName>text/plain</premis:formatName>
        </premis:formatDesignation>
        </premis:format>
        </premis:objectCharacteristics>
        <premis:originalName>González-Moreno2021_Article_ADescriptiveAnalysisOfATTRAmyl.pdf.txt</premis:originalName>
        </premis:object>
        </premis:premis>
        </xmlData>
      </mdWrap>
    </techMD>
  </amdSec>
6. <fileSec>
  1. <fileGrp USE="ORIGINAL">
    1. <file ADMID="FO_10641_2742_1" CHECKSUM="2dc05551fa3590638abb39e6d2ca1c1a" CHECKSUMTYPE="MD5" GROUPID="GROUP_BITSTREAM_10641_2742_1" ID="BITSTREAM_ORIGINAL_10641_2742_1" MIMETYPE="application/pdf" SEQ="1" SIZE="400929">
      1. <FLocat LOCTYPE="URL" href="http://ddfv.ufv.es/bitstream/10641/2742/1/Gonz%c3%a1lez-Moreno2021_Article_ADescriptiveAnalysisOfATTRAmyl.pdf" type="simple" />
      </file>
    </fileGrp>
  2. <fileGrp USE="TEXT">
    1. <file ADMID="FT_10641_2742_4" CHECKSUM="ff7568ade64998e584171ed6a158391b" CHECKSUMTYPE="MD5" GROUPID="GROUP_BITSTREAM_10641_2742_4" ID="BITSTREAM_TEXT_10641_2742_4" MIMETYPE="text/plain" SEQ="4" SIZE="41276">
      1. <FLocat LOCTYPE="URL" href="http://ddfv.ufv.es/bitstream/10641/2742/4/Gonz%c3%a1lez-Moreno2021_Article_ADescriptiveAnalysisOfATTRAmyl.pdf.txt" type="simple" />
      </file>
    </fileGrp>
  </fileSec>
7. <structMap LABEL="DSpace Object" TYPE="LOGICAL">
  1. <div ADMID="DMD_10641_2742" TYPE="DSpace Object Contents">
    1. <div TYPE="DSpace BITSTREAM">
      1. <fptr FILEID="BITSTREAM_ORIGINAL_10641_2742_1" />
      </div>
    </div>
  </structMap>
</mets>

mods

Descarregar XML

<?xml version="1.0" encoding="UTF-8" ?>

<mods:mods schemaLocation="http://www.loc.gov/mods/v3 http://www.loc.gov/standards/mods/v3/mods-3-1.xsd">
1. <mods:name>
  1. <mods:namePart>González Moreno, Juan</mods:namePart>
  </mods:name>
2. <mods:name>
  1. <mods:namePart>Losada López, Inés</mods:namePart>
  </mods:name>
3. <mods:name>
  1. <mods:namePart>Cisneros Barroso, Eugenia</mods:namePart>
  </mods:name>
4. <mods:name>
  1. <mods:namePart>García Pavía, Pablo</mods:namePart>
  </mods:name>
5. <mods:name>
  1. <mods:namePart>González Costello, José</mods:namePart>
  </mods:name>
6. <mods:name>
  1. <mods:namePart>Muñoz Beamud, Francisco</mods:namePart>
  </mods:name>
7. <mods:name>
  1. <mods:namePart>Campistol, Josep María</mods:namePart>
  </mods:name>
8. <mods:name>
  1. <mods:namePart>Fernández Torrón, Roberto</mods:namePart>
  </mods:name>
9. <mods:name>
  1. <mods:namePart>Chapman, Doug</mods:namePart>
  </mods:name>
10. <mods:name>
  1. <mods:namePart>Amass, Leslie</mods:namePart>
  </mods:name>
11. <mods:extension>
  1. <mods:dateAvailable encoding="iso8601">2022-01-27T13:13:46Z</mods:dateAvailable>
  </mods:extension>
12. <mods:extension>
  1. <mods:dateAccessioned encoding="iso8601">2022-01-27T13:13:46Z</mods:dateAccessioned>
  </mods:extension>
13. <mods:originInfo>
  1. <mods:dateIssued encoding="iso8601">2021</mods:dateIssued>
  </mods:originInfo>
14. <mods:identifier type="issn">2193-8253</mods:identifier>
15. <mods:identifier type="uri">http://hdl.handle.net/10641/2742</mods:identifier>
16. <mods:identifier type="doi">10.1007/s40120-021-00267-y</mods:identifier>
17. <mods:abstract>Introduction Transthyretin amyloidosis (ATTR amyloidosis) is a clinically heterogeneous disease caused by mutations in the transthyretin (TTR) gene or aggregation of wild-type transthyretin (ATTRwt). In Spain, there are two large endemic foci of ATTR amyloidosis caused by the Val30Met variant, with additional cases across the country; however, these data may be incomplete, as there is no centralized patient registry. The Transthyretin Amyloidosis Outcomes Survey (THAOS) is an ongoing, global, longitudinal, observational survey of patients with ATTR amyloidosis, including both inherited and wild-type disease, and asymptomatic patients with TTR mutations. This analysis aimed to gain a deeper understanding of the clinical profile of patients with ATTR amyloidosis in Spain. Methods This was a descriptive analysis of the demographic and clinical characteristics of symptomatic patients enrolled at six sites geographically dispersed throughout Spain (data cutoff: January 6, 2020). Patient data at enrollment, including genotype, demographics, and clinical presentation for symptomatic patients, were recorded. Patients were grouped by predominant phenotype based on clinical measures at enrollment: predominantly cardiac, predominantly neurologic, or mixed (cardiac and neurologic). Results There were 379 patients (58.0% male; 63.3% symptomatic) enrolled in the six THAOS sites in Spain. Predominant genotypes were the Val30Met mutation (69.1%) or ATTRwt (15.6%). Predominant phenotype distribution was neurologic (50.4%), mixed (35.8%), and cardiac (13.8%) for all symptomatic patients (n = 240); neurologic (67.8%), mixed (21.2%), and cardiac (11.0%) for symptomatic Val30Met (n = 146); and mixed (64.9%), cardiac (22.8%), and neurologic (12.3%) for symptomatic ATTRwt (n = 57). Symptomatic patients reported a range of ATTR amyloidosis signs and symptoms at enrollment, with autonomic neuropathy and sensory neuropathy common in all phenotypes. Conclusions These results from THAOS highlight the phenotypic heterogeneity associated with ATTR amyloidosis in Spain and the importance of comprehensive neurologic and cardiac evaluations in all patients with ATTR amyloidosis.</mods:abstract>
18. <mods:language>
  1. <mods:languageTerm>eng</mods:languageTerm>
  </mods:language>
19. <mods:accessCondition type="useAndReproduction">http://creativecommons.org/licenses/by-nc-nd/3.0/es/</mods:accessCondition>
20. <mods:accessCondition type="useAndReproduction">openAccess</mods:accessCondition>
21. <mods:accessCondition type="useAndReproduction">Atribución-NoComercial-SinDerivadas 3.0 España</mods:accessCondition>
22. <mods:titleInfo>
  1. <mods:title>A Descriptive Analysis of ATTR Amyloidosis in Spain from the Transthyretin Amyloidosis Outcomes Survey.</mods:title>
  </mods:titleInfo>
23. <mods:genre>article</mods:genre>
</mods:mods>

ore

Descarregar XML

<?xml version="1.0" encoding="UTF-8" ?>

<atom:entry schemaLocation="http://www.w3.org/2005/Atom http://www.kbcafe.com/rss/atom.xsd.xml">
1. <atom:id>http://hdl.handle.net/10641/2742/ore.xml</atom:id>
2. <atom:link href="http://hdl.handle.net/10641/2742" rel="alternate" />
3. <atom:link href="http://hdl.handle.net/10641/2742/ore.xml" rel="http://www.openarchives.org/ore/terms/describes" />
4. <atom:link href="http://hdl.handle.net/10641/2742/ore.xml#atom" rel="self" type="application/atom+xml" />
5. <atom:published>2022-01-27T13:13:46Z</atom:published>
6. <atom:updated>2022-01-27T13:13:46Z</atom:updated>
7. <atom:source>
  1. <atom:generator>DDFV</atom:generator>
  </atom:source>
8. <atom:title>A Descriptive Analysis of ATTR Amyloidosis in Spain from the Transthyretin Amyloidosis Outcomes Survey.</atom:title>
9. <atom:author>
  1. <atom:name>González Moreno, Juan</atom:name>
  </atom:author>
10. <atom:author>
  1. <atom:name>Losada López, Inés</atom:name>
  </atom:author>
11. <atom:author>
  1. <atom:name>Cisneros Barroso, Eugenia</atom:name>
  </atom:author>
12. <atom:author>
  1. <atom:name>García Pavía, Pablo</atom:name>
  </atom:author>
13. <atom:author>
  1. <atom:name>González Costello, José</atom:name>
  </atom:author>
14. <atom:author>
  1. <atom:name>Muñoz Beamud, Francisco</atom:name>
  </atom:author>
15. <atom:author>
  1. <atom:name>Campistol, Josep María</atom:name>
  </atom:author>
16. <atom:author>
  1. <atom:name>Fernández Torrón, Roberto</atom:name>
  </atom:author>
17. <atom:author>
  1. <atom:name>Chapman, Doug</atom:name>
  </atom:author>
18. <atom:author>
  1. <atom:name>Amass, Leslie</atom:name>
  </atom:author>
19. <atom:category label="Aggregation" scheme="http://www.openarchives.org/ore/terms/" term="http://www.openarchives.org/ore/terms/Aggregation" />
20. <atom:category scheme="http://www.openarchives.org/ore/atom/modified" term="2022-01-27T13:13:46Z" />
21. <atom:category label="DSpace Item" scheme="http://www.dspace.org/objectModel/" term="DSpaceItem" />
22. <atom:link href="http://ddfv.ufv.es/bitstream/10641/2742/1/Gonz%c3%a1lez-Moreno2021_Article_ADescriptiveAnalysisOfATTRAmyl.pdf" length="400929" rel="http://www.openarchives.org/ore/terms/aggregates" title="González-Moreno2021_Article_ADescriptiveAnalysisOfATTRAmyl.pdf" type="application/pdf" />
23. <oreatom:triples>
  1. <rdf:Description about="http://hdl.handle.net/10641/2742/ore.xml#atom">
    1. <rdf:type resource="http://www.dspace.org/objectModel/DSpaceItem" />
    2. <dcterms:modified>2022-01-27T13:13:46Z</dcterms:modified>
    </rdf:Description>
  2. <rdf:Description about="http://ddfv.ufv.es/bitstream/10641/2742/1/Gonz%c3%a1lez-Moreno2021_Article_ADescriptiveAnalysisOfATTRAmyl.pdf">
    1. <rdf:type resource="http://www.dspace.org/objectModel/DSpaceBitstream" />
    2. <dcterms:description>ORIGINAL</dcterms:description>
    </rdf:Description>
  3. <rdf:Description about="http://ddfv.ufv.es/bitstream/10641/2742/2/license_rdf">
    1. <rdf:type resource="http://www.dspace.org/objectModel/DSpaceBitstream" />
    2. <dcterms:description>CC-LICENSE</dcterms:description>
    </rdf:Description>
  4. <rdf:Description about="http://ddfv.ufv.es/bitstream/10641/2742/3/license.txt">
    1. <rdf:type resource="http://www.dspace.org/objectModel/DSpaceBitstream" />
    2. <dcterms:description>LICENSE</dcterms:description>
    </rdf:Description>
  5. <rdf:Description about="http://ddfv.ufv.es/bitstream/10641/2742/4/Gonz%c3%a1lez-Moreno2021_Article_ADescriptiveAnalysisOfATTRAmyl.pdf.txt">
    1. <rdf:type resource="http://www.dspace.org/objectModel/DSpaceBitstream" />
    2. <dcterms:description>TEXT</dcterms:description>
    </rdf:Description>
  6. <rdf:Description about="http://ddfv.ufv.es/bitstream/10641/2742/5/Gonz%c3%a1lez-Moreno2021_Article_ADescriptiveAnalysisOfATTRAmyl.pdf.jpg">
    1. <rdf:type resource="http://www.dspace.org/objectModel/DSpaceBitstream" />
    2. <dcterms:description>THUMBNAIL</dcterms:description>
    </rdf:Description>
  </oreatom:triples>
</atom:entry>

qdc

Descarregar XML

<?xml version="1.0" encoding="UTF-8" ?>

<qdc:qualifieddc schemaLocation="http://purl.org/dc/elements/1.1/ http://dublincore.org/schemas/xmls/qdc/2006/01/06/dc.xsd http://purl.org/dc/terms/ http://dublincore.org/schemas/xmls/qdc/2006/01/06/dcterms.xsd http://dspace.org/qualifieddc/ http://www.ukoln.ac.uk/metadata/dcmi/xmlschema/qualifieddc.xsd">
1. <dc:title>A Descriptive Analysis of ATTR Amyloidosis in Spain from the Transthyretin Amyloidosis Outcomes Survey.</dc:title>
2. <dc:creator>González Moreno, Juan</dc:creator>
3. <dc:creator>Losada López, Inés</dc:creator>
4. <dc:creator>Cisneros Barroso, Eugenia</dc:creator>
5. <dc:creator>García Pavía, Pablo</dc:creator>
6. <dc:creator>González Costello, José</dc:creator>
7. <dc:creator>Muñoz Beamud, Francisco</dc:creator>
8. <dc:creator>Campistol, Josep María</dc:creator>
9. <dc:creator>Fernández Torrón, Roberto</dc:creator>
10. <dc:creator>Chapman, Doug</dc:creator>
11. <dc:creator>Amass, Leslie</dc:creator>
12. <dcterms:abstract>Introduction Transthyretin amyloidosis (ATTR amyloidosis) is a clinically heterogeneous disease caused by mutations in the transthyretin (TTR) gene or aggregation of wild-type transthyretin (ATTRwt). In Spain, there are two large endemic foci of ATTR amyloidosis caused by the Val30Met variant, with additional cases across the country; however, these data may be incomplete, as there is no centralized patient registry. The Transthyretin Amyloidosis Outcomes Survey (THAOS) is an ongoing, global, longitudinal, observational survey of patients with ATTR amyloidosis, including both inherited and wild-type disease, and asymptomatic patients with TTR mutations. This analysis aimed to gain a deeper understanding of the clinical profile of patients with ATTR amyloidosis in Spain. Methods This was a descriptive analysis of the demographic and clinical characteristics of symptomatic patients enrolled at six sites geographically dispersed throughout Spain (data cutoff: January 6, 2020). Patient data at enrollment, including genotype, demographics, and clinical presentation for symptomatic patients, were recorded. Patients were grouped by predominant phenotype based on clinical measures at enrollment: predominantly cardiac, predominantly neurologic, or mixed (cardiac and neurologic). Results There were 379 patients (58.0% male; 63.3% symptomatic) enrolled in the six THAOS sites in Spain. Predominant genotypes were the Val30Met mutation (69.1%) or ATTRwt (15.6%). Predominant phenotype distribution was neurologic (50.4%), mixed (35.8%), and cardiac (13.8%) for all symptomatic patients (n = 240); neurologic (67.8%), mixed (21.2%), and cardiac (11.0%) for symptomatic Val30Met (n = 146); and mixed (64.9%), cardiac (22.8%), and neurologic (12.3%) for symptomatic ATTRwt (n = 57). Symptomatic patients reported a range of ATTR amyloidosis signs and symptoms at enrollment, with autonomic neuropathy and sensory neuropathy common in all phenotypes. Conclusions These results from THAOS highlight the phenotypic heterogeneity associated with ATTR amyloidosis in Spain and the importance of comprehensive neurologic and cardiac evaluations in all patients with ATTR amyloidosis.</dcterms:abstract>
13. <dcterms:dateAccepted>2022-01-27T13:13:46Z</dcterms:dateAccepted>
14. <dcterms:available>2022-01-27T13:13:46Z</dcterms:available>
15. <dcterms:created>2022-01-27T13:13:46Z</dcterms:created>
16. <dcterms:issued>2021</dcterms:issued>
17. <dc:type>article</dc:type>
18. <dc:identifier>2193-8253</dc:identifier>
19. <dc:identifier>http://hdl.handle.net/10641/2742</dc:identifier>
20. <dc:identifier>10.1007/s40120-021-00267-y</dc:identifier>
21. <dc:language>eng</dc:language>
22. <dc:relation>https://link.springer.com/article/10.1007%2Fs40120-021-00267-y</dc:relation>
23. <dc:rights>http://creativecommons.org/licenses/by-nc-nd/3.0/es/</dc:rights>
24. <dc:rights>openAccess</dc:rights>
25. <dc:rights>Atribución-NoComercial-SinDerivadas 3.0 España</dc:rights>
26. <dc:publisher>Neurology and Therapy</dc:publisher>
</qdc:qualifieddc>

rdf

Descarregar XML

<?xml version="1.0" encoding="UTF-8" ?>

<rdf:RDF schemaLocation="http://www.openarchives.org/OAI/2.0/rdf/ http://www.openarchives.org/OAI/2.0/rdf.xsd">
1. <ow:Publication about="oai:ddfv.ufv.es:10641/2742">
  1. <dc:title>A Descriptive Analysis of ATTR Amyloidosis in Spain from the Transthyretin Amyloidosis Outcomes Survey.</dc:title>
  2. <dc:creator>González Moreno, Juan</dc:creator>
  3. <dc:creator>Losada López, Inés</dc:creator>
  4. <dc:creator>Cisneros Barroso, Eugenia</dc:creator>
  5. <dc:creator>García Pavía, Pablo</dc:creator>
  6. <dc:creator>González Costello, José</dc:creator>
  7. <dc:creator>Muñoz Beamud, Francisco</dc:creator>
  8. <dc:creator>Campistol, Josep María</dc:creator>
  9. <dc:creator>Fernández Torrón, Roberto</dc:creator>
  10. <dc:creator>Chapman, Doug</dc:creator>
  11. <dc:creator>Amass, Leslie</dc:creator>
  12. <dc:description>Introduction Transthyretin amyloidosis (ATTR amyloidosis) is a clinically heterogeneous disease caused by mutations in the transthyretin (TTR) gene or aggregation of wild-type transthyretin (ATTRwt). In Spain, there are two large endemic foci of ATTR amyloidosis caused by the Val30Met variant, with additional cases across the country; however, these data may be incomplete, as there is no centralized patient registry. The Transthyretin Amyloidosis Outcomes Survey (THAOS) is an ongoing, global, longitudinal, observational survey of patients with ATTR amyloidosis, including both inherited and wild-type disease, and asymptomatic patients with TTR mutations. This analysis aimed to gain a deeper understanding of the clinical profile of patients with ATTR amyloidosis in Spain. Methods This was a descriptive analysis of the demographic and clinical characteristics of symptomatic patients enrolled at six sites geographically dispersed throughout Spain (data cutoff: January 6, 2020). Patient data at enrollment, including genotype, demographics, and clinical presentation for symptomatic patients, were recorded. Patients were grouped by predominant phenotype based on clinical measures at enrollment: predominantly cardiac, predominantly neurologic, or mixed (cardiac and neurologic). Results There were 379 patients (58.0% male; 63.3% symptomatic) enrolled in the six THAOS sites in Spain. Predominant genotypes were the Val30Met mutation (69.1%) or ATTRwt (15.6%). Predominant phenotype distribution was neurologic (50.4%), mixed (35.8%), and cardiac (13.8%) for all symptomatic patients (n = 240); neurologic (67.8%), mixed (21.2%), and cardiac (11.0%) for symptomatic Val30Met (n = 146); and mixed (64.9%), cardiac (22.8%), and neurologic (12.3%) for symptomatic ATTRwt (n = 57). Symptomatic patients reported a range of ATTR amyloidosis signs and symptoms at enrollment, with autonomic neuropathy and sensory neuropathy common in all phenotypes. Conclusions These results from THAOS highlight the phenotypic heterogeneity associated with ATTR amyloidosis in Spain and the importance of comprehensive neurologic and cardiac evaluations in all patients with ATTR amyloidosis.</dc:description>
  13. <dc:date>2022-01-27T13:13:46Z</dc:date>
  14. <dc:date>2022-01-27T13:13:46Z</dc:date>
  15. <dc:date>2021</dc:date>
  16. <dc:type>article</dc:type>
  17. <dc:identifier>2193-8253</dc:identifier>
  18. <dc:identifier>http://hdl.handle.net/10641/2742</dc:identifier>
  19. <dc:identifier>10.1007/s40120-021-00267-y</dc:identifier>
  20. <dc:language>eng</dc:language>
  21. <dc:relation>https://link.springer.com/article/10.1007%2Fs40120-021-00267-y</dc:relation>
  22. <dc:rights>http://creativecommons.org/licenses/by-nc-nd/3.0/es/</dc:rights>
  23. <dc:rights>openAccess</dc:rights>
  24. <dc:rights>Atribución-NoComercial-SinDerivadas 3.0 España</dc:rights>
  25. <dc:publisher>Neurology and Therapy</dc:publisher>
  </ow:Publication>
</rdf:RDF>

xoai

Descarregar XML

<?xml version="1.0" encoding="UTF-8" ?>

<metadata schemaLocation="http://www.lyncode.com/xoai http://www.lyncode.com/xsd/xoai.xsd">
1. <element name="dc">
  1. <element name="contributor">
    1. <element name="author">
      1. <element name="none">
        <field name="value">González Moreno, Juan</field>
        <field name="authority">fa7ef5b5-3e36-429f-b476-295de5cbf021</field>
        <field name="confidence">600</field>
        <field name="value">Losada López, Inés</field>
        <field name="authority">634f961b-0bc7-44e1-8b68-f15d47087519</field>
        <field name="confidence">600</field>
        <field name="value">Cisneros Barroso, Eugenia</field>
        <field name="authority">075e99bc-12eb-4054-a79b-da8365f9f32a</field>
        <field name="confidence">600</field>
        <field name="value">García Pavía, Pablo</field>
        <field name="authority">73</field>
        <field name="confidence">600</field>
        <field name="value">González Costello, José</field>
        <field name="authority">2cf97701-b4f0-4377-bcd9-34bbb813ca00</field>
        <field name="confidence">600</field>
        <field name="value">Muñoz Beamud, Francisco</field>
        <field name="authority">d646ea11-0365-4d1b-b9c7-d6ec08b589a9</field>
        <field name="confidence">600</field>
        <field name="value">Campistol, Josep María</field>
        <field name="authority">22cc147f-504c-4742-9e64-79bb03c00bee</field>
        <field name="confidence">600</field>
        <field name="value">Fernández Torrón, Roberto</field>
        <field name="authority">f56e70e6-2e95-4938-b391-089841395662</field>
        <field name="confidence">600</field>
        <field name="value">Chapman, Doug</field>
        <field name="authority">aa892c9c-da39-4329-a4ec-a3cc155fc12d</field>
        <field name="confidence">600</field>
        <field name="value">Amass, Leslie</field>
        <field name="authority">327494ff-81c0-43fe-92a5-c91629a8ac29</field>
        <field name="confidence">600</field>
        </element>
      </element>
    </element>
  2. <element name="date">
    1. <element name="accessioned">
      1. <element name="none">
        <field name="value">2022-01-27T13:13:46Z</field>
        </element>
      </element>
    2. <element name="available">
      1. <element name="none">
        <field name="value">2022-01-27T13:13:46Z</field>
        </element>
      </element>
    3. <element name="issued">
      1. <element name="none">
        <field name="value">2021</field>
        </element>
      </element>
    </element>
  3. <element name="identifier">
    1. <element name="issn">
      1. <element name="spa">
        <field name="value">2193-8253</field>
        </element>
      </element>
    2. <element name="uri">
      1. <element name="none">
        <field name="value">http://hdl.handle.net/10641/2742</field>
        </element>
      </element>
    3. <element name="doi">
      1. <element name="spa">
        <field name="value">10.1007/s40120-021-00267-y</field>
        </element>
      </element>
    </element>
  4. <element name="description">
    1. <element name="abstract">
      1. <element name="spa">
        <field name="value">Introduction Transthyretin amyloidosis (ATTR amyloidosis) is a clinically heterogeneous disease caused by mutations in the transthyretin (TTR) gene or aggregation of wild-type transthyretin (ATTRwt). In Spain, there are two large endemic foci of ATTR amyloidosis caused by the Val30Met variant, with additional cases across the country; however, these data may be incomplete, as there is no centralized patient registry. The Transthyretin Amyloidosis Outcomes Survey (THAOS) is an ongoing, global, longitudinal, observational survey of patients with ATTR amyloidosis, including both inherited and wild-type disease, and asymptomatic patients with TTR mutations. This analysis aimed to gain a deeper understanding of the clinical profile of patients with ATTR amyloidosis in Spain. Methods This was a descriptive analysis of the demographic and clinical characteristics of symptomatic patients enrolled at six sites geographically dispersed throughout Spain (data cutoff: January 6, 2020). Patient data at enrollment, including genotype, demographics, and clinical presentation for symptomatic patients, were recorded. Patients were grouped by predominant phenotype based on clinical measures at enrollment: predominantly cardiac, predominantly neurologic, or mixed (cardiac and neurologic). Results There were 379 patients (58.0% male; 63.3% symptomatic) enrolled in the six THAOS sites in Spain. Predominant genotypes were the Val30Met mutation (69.1%) or ATTRwt (15.6%). Predominant phenotype distribution was neurologic (50.4%), mixed (35.8%), and cardiac (13.8%) for all symptomatic patients (n = 240); neurologic (67.8%), mixed (21.2%), and cardiac (11.0%) for symptomatic Val30Met (n = 146); and mixed (64.9%), cardiac (22.8%), and neurologic (12.3%) for symptomatic ATTRwt (n = 57). Symptomatic patients reported a range of ATTR amyloidosis signs and symptoms at enrollment, with autonomic neuropathy and sensory neuropathy common in all phenotypes. Conclusions These results from THAOS highlight the phenotypic heterogeneity associated with ATTR amyloidosis in Spain and the importance of comprehensive neurologic and cardiac evaluations in all patients with ATTR amyloidosis.</field>
        </element>
      </element>
    2. <element name="version">
      1. <element name="spa">
        <field name="value">post-print</field>
        </element>
      </element>
    3. <element name="extent">
      1. <element name="spa">
        <field name="value">392 KB</field>
        </element>
      </element>
    </element>
  5. <element name="language">
    1. <element name="iso">
      1. <element name="spa">
        <field name="value">eng</field>
        </element>
      </element>
    </element>
  6. <element name="publisher">
    1. <element name="spa">
      1. <field name="value">Neurology and Therapy</field>
      </element>
    </element>
  7. <element name="rights">
    1. <element name="*">
      1. <field name="value">Atribución-NoComercial-SinDerivadas 3.0 España</field>
      </element>
    2. <element name="uri">
      1. <element name="*">
        <field name="value">http://creativecommons.org/licenses/by-nc-nd/3.0/es/</field>
        </element>
      </element>
    3. <element name="accessRights">
      1. <element name="spa">
        <field name="value">openAccess</field>
        </element>
      </element>
    </element>
  8. <element name="title">
    1. <element name="spa">
      1. <field name="value">A Descriptive Analysis of ATTR Amyloidosis in Spain from the Transthyretin Amyloidosis Outcomes Survey.</field>
      </element>
    </element>
  9. <element name="type">
    1. <element name="spa">
      1. <field name="value">article</field>
      </element>
    </element>
  10. <element name="relation">
    1. <element name="publisherversion">
      1. <element name="spa">
        <field name="value">https://link.springer.com/article/10.1007%2Fs40120-021-00267-y</field>
        </element>
      </element>
    </element>
  </element>
2. <element name="bundles">
  1. <element name="bundle">
    1. <field name="name">ORIGINAL</field>
    2. <element name="bitstreams">
      1. <element name="bitstream">
        <field name="name">González-Moreno2021_Article_ADescriptiveAnalysisOfATTRAmyl.pdf</field>
        <field name="originalName">González-Moreno2021_Article_ADescriptiveAnalysisOfATTRAmyl.pdf</field>
        <field name="description" />
        <field name="format">application/pdf</field>
        <field name="size">400929</field>
        <field name="url">http://ddfv.ufv.es/bitstream/10641/2742/1/Gonz%c3%a1lez-Moreno2021_Article_ADescriptiveAnalysisOfATTRAmyl.pdf</field>
        <field name="checksum">2dc05551fa3590638abb39e6d2ca1c1a</field>
        <field name="checksumAlgorithm">MD5</field>
        <field name="sid">1</field>
        </element>
      </element>
    </element>
  2. <element name="bundle">
    1. <field name="name">CC-LICENSE</field>
    2. <element name="bitstreams">
      1. <element name="bitstream">
        <field name="name">license_rdf</field>
        <field name="originalName">license_rdf</field>
        <field name="format">application/rdf+xml; charset=utf-8</field>
        <field name="size">811</field>
        <field name="url">http://ddfv.ufv.es/bitstream/10641/2742/2/license_rdf</field>
        <field name="checksum">4d01a8abc68801ab758ec8c2c04918c3</field>
        <field name="checksumAlgorithm">MD5</field>
        <field name="sid">2</field>
        </element>
      </element>
    </element>
  3. <element name="bundle">
    1. <field name="name">LICENSE</field>
    2. <element name="bitstreams">
      1. <element name="bitstream">
        <field name="name">license.txt</field>
        <field name="originalName">license.txt</field>
        <field name="format">text/plain; charset=utf-8</field>
        <field name="size">2418</field>
        <field name="url">http://ddfv.ufv.es/bitstream/10641/2742/3/license.txt</field>
        <field name="checksum">8b6e3a0bc6a1ca51936267b0e6e4740c</field>
        <field name="checksumAlgorithm">MD5</field>
        <field name="sid">3</field>
        </element>
      </element>
    </element>
  4. <element name="bundle">
    1. <field name="name">TEXT</field>
    2. <element name="bitstreams">
      1. <element name="bitstream">
        <field name="name">González-Moreno2021_Article_ADescriptiveAnalysisOfATTRAmyl.pdf.txt</field>
        <field name="originalName">González-Moreno2021_Article_ADescriptiveAnalysisOfATTRAmyl.pdf.txt</field>
        <field name="description">Extracted text</field>
        <field name="format">text/plain</field>
        <field name="size">41276</field>
        <field name="url">http://ddfv.ufv.es/bitstream/10641/2742/4/Gonz%c3%a1lez-Moreno2021_Article_ADescriptiveAnalysisOfATTRAmyl.pdf.txt</field>
        <field name="checksum">ff7568ade64998e584171ed6a158391b</field>
        <field name="checksumAlgorithm">MD5</field>
        <field name="sid">4</field>
        </element>
      </element>
    </element>
  5. <element name="bundle">
    1. <field name="name">THUMBNAIL</field>
    2. <element name="bitstreams">
      1. <element name="bitstream">
        <field name="name">González-Moreno2021_Article_ADescriptiveAnalysisOfATTRAmyl.pdf.jpg</field>
        <field name="originalName">González-Moreno2021_Article_ADescriptiveAnalysisOfATTRAmyl.pdf.jpg</field>
        <field name="description">Generated Thumbnail</field>
        <field name="format">image/jpeg</field>
        <field name="size">1792</field>
        <field name="url">http://ddfv.ufv.es/bitstream/10641/2742/5/Gonz%c3%a1lez-Moreno2021_Article_ADescriptiveAnalysisOfATTRAmyl.pdf.jpg</field>
        <field name="checksum">9b2742b4f3acecd05775bbfca139aa91</field>
        <field name="checksumAlgorithm">MD5</field>
        <field name="sid">5</field>
        </element>
      </element>
    </element>
  </element>
3. <element name="others">
  1. <field name="handle">10641/2742</field>
  2. <field name="identifier">oai:ddfv.ufv.es:10641/2742</field>
  3. <field name="lastModifyDate">2022-01-28 02:00:19.199</field>
  </element>
4. <element name="repository">
  1. <field name="name">DDFV</field>
  2. <field name="mail">dspace@ufv.es</field>
  </element>
5. <element name="license">
  1. <field name="bin">LSBFbCByZXBvc2l0b3JpbyBpbnN0aXR1Y2lvbmFsIGRlIGxhIFVuaXZlcnNpZGFkIEZyYW5jaXNjbyBkZSBWaXRvcmlhIGRlIE1hZHJpZCAoRERGViksIHBvbmUgYSBkaXNwb3NpY2nDs24gZGUgbG9zIHVzdWFyaW9zIGxhIHBsYXRhZm9ybWEgZGlnaXRhbCBhYmllcnRhIHkgZGUgYWNjZXNvIGxpYnJlIGRlIGxhIHByb2R1Y2Npw7NuIGNpZW50w61maWNhIGRlIGxhIGluc3RpdHVjacOzbi4KCi0gQSB0YWxlcyBmaW5lcywgbG9zIGF1dG9yZXMgZGVjbGFyYW4gcXVlIHNvbiB0aXR1bGFyZXMgZGUgbG9zIGRlcmVjaG9zIGRlIHByb3BpZWRhZCBpbnRlbGVjdHVhbCBkZSBsYSBvYnJhIHkgcXVlIMOpc3RhIGVzIG9yaWdpbmFsLgoKLSBNZWRpYW50ZSBsYSBhY2VwdGFjacOzbiBkZSBlc3RhIGxpY2VuY2lhLCBlbCBhdXRvciwgY29tbyB0aXR1bGFyIGRlIGxvcyBkZXJlY2hvcyBkZSBhdXRvciwgYXV0b3JpemEgeSBjZWRlIGEgbGEgVW5pdmVyc2lkYWQgRnJhbmNpc2NvIGRlIFZpdG9yaWEsIGRlIGZvcm1hIGdyYXR1aXRhIHkgbm8gZXhjbHVzaXZhLCBwb3IgZWwgbcOheGltbyBwbGF6byBsZWdhbCB5IGNvbiDDoW1iaXRvIHVuaXZlcnNhbCwgbG9zIGRlcmVjaG9zIGRlIHJlcHJvZHVjY2nDs24sIGRpc3RyaWJ1Y2nDs24sIGNvbXVuaWNhY2nDs24gcMO6YmxpY2EsIGluY2x1aWRvIGVsIGRlcmVjaG8gZGUgcHVlc3RhIGEgZGlzcG9zaWNpw7NuIGVsZWN0csOzbmljYSwgeSBsYSB0cmFuc2Zvcm1hY2nDs24gZGUgZm9ybWF0byBzb2JyZSBsYSBvYnJhIGluZGljYWRhLCBzaSBmdWVyYSBlbCBjYXNvLgoKLSBFbiBlbCBjYXNvIGRlIGNlc2nDs24gZGUgZGVyZWNob3MgZGUgZXhwbG90YWNpw7NuIGEgdGVyY2Vyb3MsIGRlY2xhcmEgcXVlIGN1ZW50YSBjb24gbGEgYXV0b3JpemFjacOzbiBkZSBkaWNob3MgdGl0dWxhcmVzIHkgcXVlIGhhIG9idGVuaWRvIGVsIHBlcm1pc28gc2luIHJlc3RyaWNjaW9uZXMgZGVsIHByb3BpZXRhcmlvIGRlbCBjb3B5cmlnaHQgcGFyYSBvdG9yZ2FyIGEgbGEgaW5zdGl0dWNpw7NuIGxvcyBkZXJlY2hvcyByZXF1ZXJpZG9zIHBhcmEgZXN0YSBsaWNlbmNpYSB5IHF1ZSBkaWNobyBwcm9waWV0YXJpbyBjb25vY2UgZWwgdGV4dG8gbyBlbCBjb250ZW5pZG8gZGUgbGEgb2JyYS4KCi0gU2kgZnVlcmEgdW5hIG9icmEgcGF0cm9jaW5hZGEgcG9yIGFsZ3VuYSBpbnN0aXR1Y2nDs24gZGlzdGludGEgYSBsYSBVbml2ZXJzaWRhZCBGcmFuY2lzY28gZGUgVml0b3JpYSwgZGVjbGFyYSBxdWUgZW4gY2FzbyBuZWNlc2FyaW8sIGN1ZW50YSBjb24gbG9zIHBlcm1pc29zIHBlcnRpbmVudGVzLCBkZSBsYSBpbnN0aXR1Y2nDs24gbyBlbnRpZGFkLCBxdWUgbGUgcGVybWl0YW4gbGEgZGlmdXNpw7NuIGRlIGRpY2hhIG9icmEuCgotIExhIFVuaXZlcnNpZGFkIEZyYW5jaXNjbyBkZSBWaXRvcmlhIG5vIHRpZW5lIGxhIHRpdHVsYXJpZGFkIGRlIGxvcyBkZXJlY2hvcyBzb2JyZSBsYSBvYnJhLCBxdWUgY29ycmVzcG9uZGVuIGFsIGF1dG9yLCBwZXJvIHNpbiBlbWJhcmdvIMOpc3RhIGxpY2VuY2lhIGRhIGRlcmVjaG8gYSByZXByb2R1Y2lybGEgZW4gdW4gc29wb3J0ZSBkaWdpdGFsLCBkaXN0cmlidWlyIGEgbG9zIHVzdWFyaW9zIGNvcGlhcyBlbGVjdHLDs25pY2FzIGRlIGxhIG9icmEgZW4gZm9ybWF0byBkaWdpdGFsLCBjb211bmljYWNpw7NuIHDDumJsaWNhIHkgc3UgcHVlc3RhIGEgZGlzcG9zaWNpw7NuIGEgdHJhdsOpcyBkZSB1biBhcmNoaXZvIGFiaWVydG8gaW5zdGl0dWNpb25hbC4KCi0gTGEgb2JyYSBzZSBwb25kcsOhIGEgZGlzcG9zaWNpw7NuIGRlIGxvcyB1c3VhcmlvcyBwYXJhIHF1ZSBoYWdhbiBkZSBlbGxhIHVuIHVzbyBqdXN0byB5IHJlc3BldHVvc28gY29uIGxvcyBkZXJlY2hvcyBkZSBhdXRvciwgc2VhIGNvbiBmaW5lcyBkZSBlc3R1ZGlvLCBpbnZlc3RpZ2FjacOzbiBvIGN1YWxxdWllciBvdHJvIGZpbiBsw61jaXRvLCB5IGRlIGFjdWVyZG8gYSBsYXMgY29uZGljaW9uZXMgZXN0YWJsZWNpZGFzIGVuIGxhIGxpY2VuY2lhIENyZWF0aXZlIENvbW1vbnMsIGRlIG1vZG8gcXVlIGxhcyBvYnJhcyBwdWVkYW4gc2VyIGRpc3RyaWJ1aWRhcywgY29waWFkYXMgeSBleGhpYmlkYXMgc2llbXByZSBxdWUgc2UgY2l0ZSBsYSBhdXRvcsOtYSB5IG5vIHNlIG9idGVuZ2EgYmVuZWZpY2lvIGNvbWVyY2lhbC4gUG9yIHRhbnRvLCBsYSBVbml2ZXJzaWRhZCBubyBhc3VtaXLDoSByZXNwb25zYWJpbGlkYWQgYWxndW5hIHBvciBsYSBmb3JtYSBlZmVjdGl2YSBlbiBxdWUgbG9zIHVzdWFyaW9zIHV0aWxpY2VuIGVsIG1hdGVyaWFsIHB1ZXN0byBhIHN1IGRpc3Bvc2ljacOzbi4KCi0gRWwgYXV0b3IgcG9kcsOhIHNvbGljaXRhciBsYSByZXRpcmFkYSBkZSBsYSBvYnJhIGRlbCByZXBvc2l0b3JpbyBwb3IgY2F1c2EganVzdGlmaWNhZGEuIAoK</field>
  </element>
</metadata>